Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$4.5 million.

  • Insight Molecular Diagnostics' Cash from Operations rose 1858.95% to -$4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.0 million, marking a year-over-year decrease of 1139.56%. This contributed to the annual value of -$20.7 million for FY2024, which is 1119.83% up from last year.
  • Insight Molecular Diagnostics' Cash from Operations amounted to -$4.5 million in Q3 2025, which was up 1858.95% from -$6.3 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Cash from Operations' 5-year high stood at -$3.8 million during Q3 2023, with a 5-year trough of -$13.3 million in Q1 2022.
  • For the 5-year period, Insight Molecular Diagnostics' Cash from Operations averaged around -$7.5 million, with its median value being -$6.8 million (2023).
  • In the last 5 years, Insight Molecular Diagnostics' Cash from Operations crashed by 8234.8% in 2021 and then soared by 6692.7% in 2023.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Cash from Operations stood at -$7.1 million in 2021, then tumbled by 36.56% to -$9.6 million in 2022, then soared by 54.15% to -$4.4 million in 2023, then fell by 21.5% to -$5.4 million in 2024, then increased by 16.24% to -$4.5 million in 2025.
  • Its Cash from Operations was -$4.5 million in Q3 2025, compared to -$6.3 million in Q2 2025 and -$5.9 million in Q1 2025.